@article{835d2089155e45bebeadc2d0a1afe3c5,
title = "Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America",
abstract = "Evidence-based guidelines for the management of persons infected with human immunodeficiency virus (HIV) were prepared by an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America. These updated guidelines replace those published in 2009. The guidelines are intended for use by healthcare providers who care for HIV-infected patients. Since 2009, new antiretroviral drugs and classes have become available, and the prognosis of persons with HIV infection continues to improve. However, with fewer complications and increased survival, HIV-infected persons are increasingly developing common health problems that also affect the general population. Some of these conditions may be related to HIV infection itself or its treatment. HIV-infected persons should be managed and monitored for all relevant age-and sex-specific health problems. New information based on publications from the period 2009-2013 has been incorporated into this document.",
keywords = "HIV, HIV metabolic, HIV monitoring, HIV vaccines, guidelines, primary care, sexually transmitted diseases",
author = "Aberg, {Judith A.} and Gallant, {Joel E.} and Ghanem, {Khalil G.} and Patricia Emmanuel and Zingman, {Barry S.} and Horberg, {Michael A.}",
note = "Funding Information: Potential conflicts of interest. The following list is a reflection of what has been reported to IDSA. To provide thorough transparency, IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest (COI) is determined by a review process that includes assessment by the Standards and Practice Guidelines Committee (SPGC) Chair, the SPGC liaison to the development panel, and the Board of Directors liaison to the SPGC and, if necessary, the COI Task Force of the Board. This assessment of disclosed relationships for possible COI will be based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. For activities outside of the submitted work, J. A. A. served on the advisory board for Abbvie, Janssen (Tibotec), Merck, and ViiV, and received research grants from the National Institutes of Health, Kowa, Gilead, and Wyeth/Pfizer. For activities outside of the submitted work, J. E. G. has received grants from Gilead, Bristol-Myers Squibb, Vertex Pharmaceuticals, and ViiV. Also outside of the submitted work, he has received personal fees from Gilead, Bristol-Myers Squibb, Janssen, Merck, ViiV, and GlaxoSmithKline. He is also a member of the Department of Health and Human Services panel for adult and adolescent antiretroviral therapy guidelines. For activities outside of the submitted work, B. S. Z. received grants from Gilead, ViiV, GlaxoSmithKline, and Siemens. All other authors report no potential conflicts.",
year = "2014",
month = jan,
day = "1",
doi = "10.1093/cid/cit665",
language = "English (US)",
volume = "58",
pages = "e1--e34",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "1",
}